Zomedica Corp. Common Shares (ZOM) analyst actions
Rating and price-target actions on ZOM in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the ZOM overview →
1 measured ZOM analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Zomedica Announces Record Fourth Quarter Revenue of $10.5 Million and Full Year Revenue of $32.0 Million for 2025, Reflecting 17% Annual Growth; Achieves 68% Gross Margin and Maintains $53.3 Million in Liquidity | Press release | +3.39% | +1.94% |
Keep exploring
More ZOM: earnings → · SEC filings → · ZOM overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Matinas Biopharma Holdings, Inc. (MTNB) | 161 | -0.53% | 39% |
| NanoVibronix, Inc. (NAOV) | 161 | -0.40% | 39% |
| AVITA MEDICAL (AVMXY) | 160 | 0.00% | 46% |
| Adaptimmune Therapeutics plc - American Depositary Shares (ADAP) | 159 | -1.17% | 27% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.